Sellas' Cancer Vaccine Cuts Death Risk By 41% In Phase 3 Leukemia Trial

SELLAS Life Sciences (SLS) reported that its cancer vaccine, galinpepimut-S, met the primary survival endpoint in a Phase 3 trial for acute myeloid leukemia. The vaccine reduced death risk by 41% compared to standard treatment, with median survival of 24 months versus 14.7 months. The company plans to discuss FDA filing strategy in 2027. SLS shares rose 7.10% in pre-market trading.

Original reporting
Published Nov 17, 2026, 12:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 12:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Sellas' Cancer Vaccine Cuts Death Risk By 41% In Phase 3 Leukemia Trial — source image
Decision brief

The 30-second read

$SLSBullishMed
01

Why it matters

The disclosed primary endpoint success (overall survival) with a reported 41% reduction in death risk and median OS improvement is a material de-risking event for SELLAS, shifting focus to FDA engagement and the planned biologics license application preparations in 1H 2027.

02

Market read

Traders can reassess approval probability and timeline expectations based on the reported overall survival benefit and the stated plan to meet the FDA and prepare a BLA in 1H 2027.

03

What to watch

The article does not quantify effect robustness across secondary endpoints or provide hazard ratios, statistical significance details, or comparator specifics beyond “investigator-selected best available treatment,” which can matter for regulatory and market follow-through.

Relevance 8/10Novelty 8/10Timing: pre-market and early session reaction to Phase 3 REGAL primary endpoint results

Background

Galinpepimut-S (GPS) is an investigational cancer vaccine intended to stimulate an immune response against WT1-expressing AML cells; it is being advanced in a pivotal Phase 3 REGAL trial for patients in second or later remission who cannot undergo allogeneic stem-cell transplant.

Company-level read

Ticker impact

$SLSBullishMedium confidence
Context

SELLAS reported Phase 3 REGAL trial success for galinpepimut-S, saying it met the primary overall survival endpoint and cut death risk by 41%.

Expected impact

Likely upward bias as traders price in higher odds for a 2027 FDA biologics license application, despite remaining uncertainty around confirmatory details and FDA review.

Evidence & confidence

The article provides specific efficacy magnitude (41% death-risk reduction, median OS 24 vs 14.7 months) plus a concrete next step (FDA meeting and BLA preparations in 1H 2027), which are decision-relevant for biotech risk.

Market effects

Reinforces investor appetite for WT1-targeted immunotherapies and AML maintenance strategies, potentially lifting sentiment across small-cap oncology vaccine/biotech peers.

Primarily US small-cap biotech sentiment; limited direct cross-region spillover implied by the company-specific trial update.

Moderate global relevance for AML treatment development, but the catalyst is company-specific and tied to US FDA filing strategy.

Counterpoint

A Phase 3 overall survival endpoint meeting headline does not guarantee FDA approval; open-label design, patient selection, and future subgroup/confirmatory analyses could temper enthusiasm.

Key entities

  • SELLAS Life Sciences Group, Inc.

    Sponsor of the investigational AML vaccine galinpepimut-S and reporter of Phase 3 REGAL overall survival results.

  • Galinpepimut-S (galinpepimut-S, GPS)

    Investigational cancer vaccine designed to target WT1-expressing cancer cells.

  • REGAL trial

    Pivotal Phase 3 study in acute myeloid leukemia reporting overall survival as the primary endpoint.

  • FDA

    Planned meeting target to discuss filing strategy and biologics license application preparations.

Related articles

$SLSHighAI 9/10

SELLAS Life Sciences stock soars 240% on positive cancer trial

SELLAS Life Sciences (NASDAQ:SLS) shares rose 240% after reporting positive Phase 3 trial results for its cancer vaccine, GPS. The trial met its primary endpoint, showing a 41% reduction in death risk and improved median survival. The company plans to discuss an accelerated FDA filing strategy. GPS was well-tolerated with mild to moderate side effects.

$SLSHighAI 9/10

Sellas’ GPS Cuts Death Risk By 41% In Pivotal AML Trial – Firm Eyes FDA Filing In First Half Of 2027

Sellas Life Sciences (SLS) reported that its experimental cancer vaccine, GPS, met its primary goal in a Phase 3 trial, reducing the risk of death by 41% in AML patients. The trial showed a median overall survival of 24 months vs. 14.7 months for the control group. The company plans to file for FDA approval in the first half of 2027. SLS shares rose 7.1% pre-market before trading was halted.

$SLSHighAI 9/10

SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Ov

SELLAS Life Sciences (NASDAQ: SLS) reported positive Phase 3 REGAL trial results for its cancer vaccine, GPS, showing a 41% reduction in death risk and median OS of 24.0 months vs. 14.7 months for standard treatment. The company plans to meet with the FDA to discuss regulatory path. GPS was well-tolerated with no new safety signals. SELLAS will host a webcast to discuss results and next steps.

$SLSMedAI 8/10

SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a…

SELLAS Life Sciences Group, Inc. (SLS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid

$NVDAMed

Stocks making the biggest moves premarket: Disney, Home Depot, Nvidia & more

Coherent, Applied Optoelectronics, and Lumentum shares rose 11%, 8.6%, and 5.6% respectively, following a Reuters report on potential U.S. restrictions on Chinese data center equipment. Sellas Life Sciences shares gained over 7% after positive trial results for its cancer vaccine. Nvidia shares rose 1% ahead of earnings, despite a 25% stake reduction in Intel. Home Depot shares fell 2% with a CEO transition.

$SLSHighAI 8/10

SLS, IBRX And IOVA Join Merck And Lilly On BlackRock’s Q3 Buy List — A Vanguard Unit Adds All Of Them Too

BlackRock and a Vanguard unit added SLS, IBRX, IOVA, MRK, and LLY to their Q3 buy lists. Lilly reported strong sales from diabetes, obesity, and cancer drugs. Sellas (SLS) awaits Phase 3 trial results for its AML treatment. ImmunityBio (IBRX) plans expanded FDA approval for Anktiva. Iovance (IOVA) saw 77% YoY sales growth for Amtagvi and is testing it with Merck's (MRK) Keytruda. Retail sentiment varies across stocks.